# OnCo record idea-prostate-randomise-the-sequence-not-only-the-drugs (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-prostate-randomise-the-sequence-not-only-the-drugs" ;
  schema:name "Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer"@en ;
  schema:alternateName "sequencing trial prostate cancer"@en, "PFS2 strategy trial"@en, "treatment order randomised prostate"@en ;
  schema:description "Metastatic prostate cancer now has six classes of treatment that work, and no trial has ever compared the orders they can be given in. Every trial adds a drug to the front; none asks what should follow it, so the sequence a man receives is decided by habit and by what was licensed first."@en ;
  schema:url <https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "prostate-evidence" ;
  onco:related <https://onco.cc/ideas/idea-tr1-standing-platform-per-cancer/>, <https://onco.cc/ideas/idea-tr1-smart-designs-for-adaptive-strategies/>, <https://onco.cc/ideas/idea-bio1-alternating-schedules/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/roadmaps/trial-modernisation-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/hormonal/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/psma-pet/> ;
  onco:drugs <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/drugs/olaparib/> ;
  onco:terms <https://onco.cc/terms/radiographic-progression-free-survival/>, <https://onco.cc/terms/metastasis-free-survival/>, <https://onco.cc/terms/bipolar-androgen-therapy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-incentive-misalignment/>, <https://onco.cc/bottlenecks/b-funding-allocation/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/>, <https://onco.cc/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/>, <https://onco.cc/key-papers/paper-therap-lancet-2021/>, <https://onco.cc/key-papers/paper-vision-nejm-2021/>, <https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/>, <https://onco.cc/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/> .